最初 发表于 2025-3-27 00:12:12
http://reply.papertrans.cn/17/1642/164131/164131_31.png死亡 发表于 2025-3-27 04:44:12
http://reply.papertrans.cn/17/1642/164131/164131_32.png使坚硬 发表于 2025-3-27 08:54:33
Gabriele Hooffacker,Robert Kohlickhave a crucial role in characterizing disease, the testing activity of novel therapies, and proper evaluation of therapeutic efficacy. Traditionally, treatment response evaluation in oncology is based on comparing the size or volume of the tumor before and after treatment. The introduction of molecuflorid 发表于 2025-3-27 11:13:38
http://reply.papertrans.cn/17/1642/164131/164131_34.png新星 发表于 2025-3-27 16:50:34
http://reply.papertrans.cn/17/1642/164131/164131_35.pnglabyrinth 发表于 2025-3-27 21:39:28
http://reply.papertrans.cn/17/1642/164131/164131_36.png卵石 发表于 2025-3-27 23:40:36
http://reply.papertrans.cn/17/1642/164131/164131_37.pnghazard 发表于 2025-3-28 02:43:18
http://reply.papertrans.cn/17/1642/164131/164131_38.png责问 发表于 2025-3-28 06:43:29
Jean-François Mertens,Sylvain Sorint of disease, such as CT evaluation using the Response Evaluation Criteria in Solid Tumors (RECIST). However, such measurements are of limited value following radiotherapy. The challenge of determining the presence or absence of viable tumor within residual masses following radiotherapy provides a cESO 发表于 2025-3-28 14:23:40
http://reply.papertrans.cn/17/1642/164131/164131_40.png